NDAORALTABLETPriority Review
Approved
Apr 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
29
Data completeness
7/8 — Comprehensive
Priority Review
CAPRELSA (vandetanib) by Sanofi is protein kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2011.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAPRELSA (vandetanib) is an oral protein kinase inhibitor approved in 2011 for treating medullary thyroid cancer and other kinase-driven malignancies. It works by blocking multiple receptor tyrosine kinases to inhibit tumor cell proliferation and angiogenesis. The drug represents a targeted small-molecule approach to precision oncology.
$3MPart D
LOE ApproachingDeclining
1.9 years to LOEWith less than 2 years to LOE, CAPRELSA teams are focused on maximizing remaining exclusivity and preparing transition strategies; modest commercial footprint suggests smaller brand organization.
Mechanism of Action
Protein Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (29)
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
Started May 2017
8 enrolled
Carcinoma, HepatocellularMetastatic Colorectal Cancer
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
Started Apr 2015
160 enrolled
Neoplasms
Vandetanib in Advanced NSCLC With RET Rearrangement
Started Nov 2014
17 enrolled
Non Small Cell Lung Cancer
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Started Oct 2014
0PhaeochromocytomaParaganglioma
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
Started Apr 2014
10 enrolled
Metastatic Medullary Thyroid Cancer
Worked on CAPRELSA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.